anti-CD19 CAR NK cells

BIOLOGICAL4 trials

Sponsors

Allife Medical Science and Technology Co., Ltd., Changhai Hospital

Conditions

Autoimmune DiseasesDiffuse Large B Cell LymphomaNephropathyRefractory B-Cell Lymphoma

Early Phase 1

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Allife Medical Science and Technology Co., Ltd.Refractory B-Cell Lymphoma

Start: 2019-03-31End: 2021-11-30Target: 9Updated: 2019-01-31

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

Changhai HospitalDiffuse Large B Cell Lymphoma

Start: 2023-03-01End: 2024-12-30Target: 12Updated: 2023-08-28

An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy

RecruitingNCT06469190

Changhai HospitalNephropathy

Start: 2024-06-21End: 2027-06-20Target: 36Updated: 2026-06-26

Phase 1

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

RecruitingNCT06464679

Changhai HospitalAutoimmune Diseases

Start: 2024-06-27End: 2026-06-30Target: 72Updated: 2025-08-29